|
| Press Releases |
|
 |
|
| Thursday, September 4, 2025 |
|
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data on the selective orexin 2 receptor agonist (OX2R) E2086 and the latest findings on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO(R)) at the World Sleep Congress (World Sleep 2025) to be held in Singapore from September 5 to 10. more info >> |
|
| Wednesday, September 3, 2025 |
|
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai has initiated the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, September 1, 2025 |
|
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for once weekly lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIKTM, pronounced "I Click") for maintenance dosing. more info >> |
|
| Friday, August 29, 2025 |
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (genericname, product name "Tazverik(R) Tablets 200 mg", "tazemetostat") for unresectable INI1*2-negative epithelioid sarcoma that has progressed after chemotherapy, from the Ministry of Health, Labour and Welfare (MHLW). more info >> |
|
| Monday, August 25, 2025 |
|
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the anti-amyloid beta (AB) monoclonal antibody "LEQEMBI(R)" has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. more info >> |
|
|
エーザイとバイオジェン、アルツハイマー病治療剤「レケンビ」（レカネマブ）をドイツ、オーストリアにおいて新発売 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A.Viehbacher、以下 バイオジェン）は、このたび、抗 Aβモノクローナル抗体「レケンビ」（一般名：レカネマブ）について、オーストリアで 8 月 25 日に、ドイツでは 9 月 1 日にそれぞれ新発売することをお知らせします。 more info >> |
|
| Monday, August 18, 2025 |
|
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO(R) (brand name in China: "DAYVIGO(R)" generic name: lemborexant) has launched in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
| Thursday, July 31, 2025 |
|
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025). more info >> |
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually more info >> |
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
西藏智汇矿业登陆港股：从高原走向国际 独特资源禀赋释放长期增长潜力
Dec 19, 2025 16:15 HKT/SGT
|
|
|
西藏智匯礦業登陸港股：從高原走向國際 獨特資源稟賦釋放長期增長潛力
Dec 19, 2025 15:35 HKT/SGT
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 11:30: JST
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025 10:30 HKT/SGT
|
|
|
トヨタ、米国生産トヨタ車の26年からの日本導入を検討
Dec 19, 2025 10:00: JST
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Dec 19, 2025 3:24 JST
|
|
|
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Dec 19, 2025 3:06 JST
|
|
|
Fujitsu to showcase mobility and physical AI tech at CES 2026
Dec 19, 2025 2:42 JST
|
|
|
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Dec 19, 2025 2:06 JST
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.
Dec 18, 2025 22:00 JST
|
|
|
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM
Dec 18, 2025 18:09 HKT/SGT
|
|
|
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping
Dec 18, 2025 17:44 HKT/SGT
|
|
|
臥安機器人今起招股 獲9家豪華基石陣容超7億港元認購 募集資金超10億港元
Dec 18, 2025 14:09 HKT/SGT
|
|
|
卧安机器人今起招股 获9家豪华基石阵容超7亿港元认购 募集资金超10亿港元
Dec 18, 2025 14:09 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
